🔗 Share this article

A shadow economy for unapproved slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Experimental Drug Gaining Popularity Via Social Media

The experimental drug, which remains in research studies, is being advertised by social media influencers for its supposed fat-burning properties. Followers are urged to contact these profiles directly for source information, while also receiving promotional offers.

Thriving Commerce on Social Networks

Additionally, a robust market exists on Telegram, where groups with numerous of members share comparison images, administration instructions and assertions of next-day UK delivery. Sellers market the substance there before directing buyers to WhatsApp for purchases.

Understanding The Experimental Drug

This medication is an experimental injectable developed by US drugmaker Eli Lilly. The drug targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients lose up to 25% of their total weight. Referred to as the “triple G”, the drug is being hailed online as the successor to Ozempic.

Healthcare Professionals Voice Concerns

However, doctors and chemists have cautions that the sale of what is still an unlicensed medication in the UK is a cause for concern and could result in users administering products of uncertain source.

Some experts stated the popularity for retatrutide could be linked to the rising cost of licensed slimming treatments such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on TikTok or messaging apps is prohibited in the UK, as it is an unlicensed medication that must not be promoted or distributed for human use under the British medical regulations.

Several content creators try to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but promotion and supply can still violate medicines, marketing, and consumer regulations, risking penalties, legal action or imprisonment.

Service Reaction and Content Elimination

According to the social media company, the platform has removed problematic content and banned associated hashtags and search suggestions. The organization stated it was committed to maintaining the service secure and investing in strengthening compliance measures.

Digital Trading Activities

Research also discovered communities with up to 9,000 participants selling the experimental drug using the platform's built-in search feature, which operates like a online catalog. Entering “retatrutide” instantly brings up channels with thousands of members, filled with photos of weight loss, glowing reviews and detailed guides for preparing or administering at home.

After minutes of entering one community, a seller posted WhatsApp details, where the majority of transactions take place. The seller provided an guidebook and promised delivery within 48 hours. When questioned whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. Not one asked about body mass, medical conditions or past usage.

Product Information and Pricing

Inside these groups, messages show black plastic packages with postal service stickers, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at residence with sterile water, or pre-filled pens typically sold at £160 for 20 milligrams. When asked how long a pen should last, vendors give conflicting responses ranging from a several days to “depends on your body”.

Service Oversight and Security Measures

A representative for Telegram stated it regularly monitored harmful material on its service including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“People are injecting materials they cannot confirm. Even if the science behind this drug is sound, these digital products may not contain what they claim,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service connected the increase in interest to recent cost increases for authorized weight-loss medications such as Mounjaro. “With costs rising, individuals are turning to online platforms. But fake treatments are highly dangerous. You can’t be certain what’s contained or whether the environment they were made in was clean,” she said.

Her staff has already encountered patients harmed by self-injection from unverified suppliers. “We understand the frustration, but purchasing from messaging apps or communication platforms is taking chances with your health,” said Wyllie. “These materials could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from Eli Lilly said the substance was in phase 3 clinical trials and had not been reviewed or authorized by any government authority globally. “Consequently at this time no one can market [it] for human use,” they explained, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may subject patients to potentially significant health risks”.